Compliance-Assured RLD & Comparator Sourcing Oversight
Regulatory-assured sourcing of reference listed drugs (RLDs) and comparator products for ANDA, MAA, biosimilar, and complex generic development programs — delivered with full GDP compliance oversight and audit-ready documentation.
Axentra Global Pharma Compliance provides end-to-end coordination of comparator drug sourcing while serving as your independent GDP compliance and regulatory assurance partner. Our approach focuses not only on securing supply, but on ensuring every comparator shipment stands up to regulatory scrutiny during audits and inspections.
Global regulators increasingly examine comparator sourcing documentation during ANDA, MAA, and biosimilar submissions. Missing temperature records, unclear chain-of-custody, unqualified wholesalers, or incomplete traceability frequently become avoidable inspection observations and filing deficiencies. Axentra exists to eliminate this risk.
Comparator Sourcing Coordination
Axentra provides full operational coordination of comparator procurement across global markets:
-
Identification and qualification of licensed wholesalers and legal supply sources
-
Verification of reference standard matching (strength, dosage form, route of administration, label identity, market of origin)
-
Cross-border availability assessments where local sourcing is restricted or limited
-
Sponsor ↔ wholesaler procurement coordination
-
Import/export documentation support
-
Shipping route planning using GDP-certified cold-chain couriers
-
Delivery scheduling aligned to bioavailability studies, stability programs, and dossier timelines
Our coordination ensures that comparator material sourcing is practical, compliant, and aligned with development schedules — without exposing sponsors to unverified traders or documentation gaps.
Regulatory Documentation & Audit Dossier Preparation
Axentra compiles regulator-ready comparator sourcing documentation packages used for dossier submission and audit defense:
-
Comparator sourcing justification statements
-
Licensed wholesaler certification records
-
Cold-chain logistics qualification documentation
-
Temperature monitoring logs and excursion assessments
-
Chain-of-custody flow diagrams
-
GDP compliance declarations
-
QA certification letters
-
Audit-ready comparator sourcing master files for ANDA, MAA, biosimilar dossiers
-
Regulatory inspection response support
Our documentation packages are designed to stand alone during regulatory inspection requests, minimizing sponsor exposure to sourcing-related findings.
GDP Compliance Oversight
This is Axentra’s primary value differentiator.
We function as an independent GDP compliance overlay across the comparator supply chain:
-
Supplier qualification and documentation verification for licensed wholesalers
-
Courier qualification and GDP logistics partner review
-
Storage condition verification and distribution compliance checks
-
Temperature monitoring data review
-
Chain-of-custody mapping from source to site delivery
-
Deviation and temperature excursion assessment documentation
-
Retrieval of corrective action statements from logistics partners where applicable
-
Complete distribution traceability compilation
This oversight framework ensures that sponsors maintain defensible compliance records to support regulatory submissions and inspection questioning.
Biosimilar development programs
Requiring tightly controlled comparator sourcing
Contract Research Organizations (CROs)
Supporting global BE and PK studies
Virtual pharma companies
Lacking internal GDP and sourcing infrastructure
Who we support
Geographic Coverage
Axentra coordinates comparator sourcing across the globe
United States
European Union & United Kingdom
India and South East Asia
UAE and Select ROW market
Therapy Areas Supported
Axentra specializes in high-complexity comparator programs, including
Injectables and sterile dosage forms
Biologics & Biosimilars
Cold-Chain Therapies (GLP-1, Oncology Biologics, Vaccines)
Modified-Release & Specialty Oral Dosage Forms
High-Value First-Generic Comparator Materials
Why Sponsors Choose Axentra
Axentra focuses on regulatory defensibility.
Sponsors select Axentra because we provide:
-
Compliance-first sourcing — not procurement brokerage
-
Deep understanding of FDA, EMA and global inspection expectations
-
Independent GDP oversight documentation
-
ICU-level cold-chain compliance coordination
-
Inspection-grade chain-of-custody traceability
-
Regulatory dossier expertise integrated into sourcing workflows
Our background as regulatory compliance professionals — not trading intermediaries — defines our delivery standards.
RLD & Comparator Drug Sourcing— Frequently Asked Questions
What documentation does a comparator batch need?
Enough to establish an unbroken chain of custody: supplier identification, batch and lot numbers, certificate of analysis, expiry, and storage and transport records covering the whole journey. If the product is temperature sensitive, that includes the temperature record, not just a statement that cold chain was maintained.
How do you source a reference listed drug for a bioequivalence study?
By identifying the correct reference product for the intended market, confirming batch availability against the study timeline, and buying through a documented, GDP-compliant channel. The constraint is usually timing — a batch with too little remaining shelf life cannot support the study.
Why does GDP-compliant sourcing matter for a filing?
Because a regulator assessing bioequivalence data needs confidence that the comparator was genuine and correctly handled. Gaps in the sourcing record are a data integrity question, and they are difficult to remedy after the study has run.